Connect your AI

Shattuck Labs, Inc. STTK AFS Securities

AFS Securities at other companies

Aclaris TherapeuticsACRS

$85.37M+0.2%

ZymeworksZYME

$159.47M-35.0%

Nektar TherapeuticsNKTR

$162.99M+7,973%

Arcus BiosciencesRCUS

$54M+575%

Other financials

Income statement

Revenue-—

Operating income-$15.5M-8.0%

Net income-$14.8M-7.8%

EPS (diluted)-$0.13+51.9%

Balance sheet

Cash & equivalents$90.4M+48.5%

Total debt$2.9M-9.5%

Total equity$95.8M+41.8%

Total assets$102.1M+32.3%

Cash flow

Operating cash flow-$13.4M-11.6%

CapEx$63.0K—

Free cash flow-$13.5M-12.1%

Valuation

Market cap$564.45M+1,131%

Enterprise value$476.92M-4,119%

P/S564.5×+554×

Profitability

Operating margin-5,266.4%-9,520pp

Net margin-4,987.4%-8,966pp

FCF margin-4,140.8%-7,144pp

Returns & leverage

Return on equity-61%-8.0pp

Debt / equity0×0.0×

Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Shattuck Labs, Inc.'s AFS securities?: Shattuck Labs, Inc. (STTK) reported AFS securities of $88.86M in Q1 2026.
How has Shattuck Labs, Inc.'s AFS securities changed year-over-year?: Shattuck Labs, Inc.'s AFS securities increased by 48.6% year-over-year, from $59.79M to $88.86M.
What is the long-term trend for Shattuck Labs, Inc.'s AFS securities?: Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s AFS securities has grown at a -22.2% compound annual growth rate (CAGR), from $125.8M to $76.14M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.